Regeneron CEO Len Schleifer ripped into Amgen for its insistence on blocking sales of a rival cholesterol drug during the appeals process in a patent infringement case.
Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Leadership representing the 2018 Manny Award agency and network winners and finalists share their views on various healthcare industry trends and developments.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
A recent study of DTC advertising appearing in the Journal of General Internal Medicine concluded that few broadcast ads are compliant with FDA’s guidelines. The reality, though, might not be so cut and dried.
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
On Oct. 28, 2016, my mother, Joan Biamonte, died of complications from metastatic carcinoma of the lung. Despite having her original tumor characterized and going through a regimen of chemotherapy allegedly tailored to her tumor type, her cancer proliferated and spread into her liver and brain.
Drugs recently approved around the world to fight cancer increased patients’ overall survival, but benefits vary depending on the drug, a new study shows.
Democrats are showing little interest in cooperating with the Republicans who control Congress on legislation to dismantle the Obamacare health insurance law, but some are signaling a willingness to collaborate on action to curb rising drug prices.
Express Scripts Holding Co. – the largest pharmacy benefit manager in the United States – signaled that scrutiny into drug pricing is not going away.
Two leading U.S. medical societies are poised to issue new diabetes treatment guidelines that are expected to reflect the lifesaving cardiovascular effects of Eli Lilly’s Jardiance.
Global spending on prescription medicines will reach nearly $1.5 trillion by 2021, although the annual rate of growth will decrease from recent years, according to a forecast by Quintiles IMS Holding.
Management from 2016 Manny Award winners and finalists weigh in on various industry topics presented to them by Med Ad News.
Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes, sparking a fresh battle for sales in a fiercely competitive market.
The National Institute for Clinical Excellence has finally given backing for the NHS’ approval of Perjeta for human epidermal growth factor receptor 2-positive breast cancer.